Featured Press Releases

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy

  • 23 Apr 2024

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and...

GenScript

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

Bruker Acquires Majority Stake in RECIPE, a Leader in Mass Spectrometry-Based Diagnostic Assays for Therapeutic Drug Monitoring

Bruker Acquires Majority Stake in RECIPE, a Leader in Mass Spectrometry-Based Diagnostic Assays for Therapeutic Drug Monitoring

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

  • Erbe Elektromedizin GmbH
  • 03 Dec 2025
Within one year of its launch, L&C Bio

Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism

  • L&C BIO Co., Ltd
  • 03 Dec 2025
Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

  • Celltrion
  • 01 Dec 2025
Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

  • Samsung Bioepis Co., Ltd.
  • 01 Dec 2025
Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

  • Menarini Industrie Farmaceutiche Riunite
  • 25 Nov 2025
Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

  • Eisai Inc.
  • 25 Nov 2025
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
December   2025
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.